H. Lundbeck A/S has appointed Jens Peter Balling, a safety expert, to the position of vice president regulatory affairs, pharmacovigilance and clinical quality assurance following a reorganisation of the company’s research and development activities. The reorganisation consolidates the company’s activities in this area in order to enable management to oversee an increase in clinical research. Concurrently, it has also appointed Iman Barilero as vice president of regulatory development strategy and policy. Ms Barilero joined Lundbeck in 2007 as a divisional director in regulatory affairs having previously worked at Hoffmann-La Roche and Johnson & Johnson. Mr Balling has been an executive with Lundbeck since 2006. Prior to that he worked at Novo Nordisk and Nycomed.
Copyright 2011 Evernow Publishing Ltd